Dr Mike Lynch OBE FREng FRS
Founder, Technology Entrepreneur

Mike is a celebrated technologist and has a proven track record of identifying and monetising fundamental technologies.

Having pioneered three of the biggest success stories in UK tech, Autonomy, Blinkx and Darktrace, Mike is regarded as Britain's most established technology entrepreneur. Spun out from his previous company, Neurodynamics, which he sold in 2005, Mike founded Autonomy in 1996 based on technology invented at Cambridge University, where Dr Lynch studied Information Sciences, received a Ph.D. and held a research fellowship in adaptive pattern recognition. He served as CEO of Autonomy for over fifteen years, during which time it became one of the UK's most successful technology companies on the FTSE100. Autonomy was acquired by HP for $11 billion in 2011.

Mike founded Invoke Capital in 2012 to support world-leading fundamental technology businesses emerging across Europe. Since then, Invoke has been instrumental in developing and scaling prominent UK tech companies from innovative start-ups out of Cambridge University into global businesses. Portfolio companies include Luminance, an award-winning machine learning platform for the legal industry, and Darktrace, a world-leading cyber AI company that employs more than 800 people globally.

Referred to as the UK’s answer to Bill Gates, Mike has won numerous awards, including Computer Weekly's 'Most Influential Person of the Year' and the Chartered Institute for IT's award for Outstanding Contribution to IT in 2011. He was awarded an OBE for Services to Enterprise in 2006 and was elected to the Prime Minister’s Council for Science and Technology in 2011. Mike is a fellow of the Royal Academy of Engineering and an honorary fellow of Christ's College Cambridge. He was also elected a Fellow of the Royal Society in April 2014 and a trustee of the National Endowment for Science Technology and the Arts ( NESTA ) in 2010.

Mike is a generous supporter of many causes, including the Royal Botanic Gardens - Kew, Cancer Research UK, Cambridge University, The Prince’s Trust’s technology group and a number of educational charities. He also contributes to conservation charities and preserves rare breeds.

Dr Pete Menell
Technology R&D

Pete held the position of Chief Technology Officer of Autonomy for twelve years, heading up R&D and technical support teams globally. He was responsible for the development of Autonomy's fundamental technology platform, and is an expert in rapidly integrating core technologies into legacy software. During his academic career, Pete conducted significant computational and neuro-physiology research.

He holds a BA ( Hons ) and MSc in Computer Science from York University and a D.Phil in physiology from Oxford University.

Vanessa Colomar
Communications & Investor Relations

Vanessa's expertise is in PR and communications, having held senior positions at agency Edelman and Burston Marsteller in Madrid and New York. She served as SVP of Communications at Autonomy, then the UK’s largest technology company, which sold to HP for $11billion in 2011.

Vanessa is a Partner and Co-Founder of Invoke Capital. At Invoke, Vanessa is responsible for Communications and Investor Relations and oversees these functions for portfolio companies including Darktrace and Luminance. She sits on the Board of Directors for Darktrace, the world’s leading cyber security company, and Luminance, the leading AI platform for the legal industry.

Vanessa holds a First-Class BA in Modern European Languages from Durham University, and an MA in Journalism from Universidad Autónoma de Madrid. She is bilingual in Spanish and English, and conversational in Italian and French.

Andrew Kanter
Non-Executive Partner

Andrew Kanter served as Chief Operating Officer and General Counsel of Autonomy for twelve years, where he led its global legal and operations divisions and oversaw all major acquisitions and transactions. A qualified lawyer, Andrew was previously an attorney in private practice in San Francisco and London, specialising in venture capital, international M&A and corporate finance. Andrew also served as Clerk to Hon. Christine Miller of the US Court of Federal Claims, Washington D.C.

He holds a J.D. from the University of Southern California Law Center and a BA from Johns Hopkins University.

Phil Pearson

Phil has spent the majority of his career investing in publicly-listed global technology, media and telecom companies. He was a Portfolio Manager for leading fund manager GLG Partners and most recently at UBS O’Connor.

In his role at Invoke Capital, Phil is responsible for the discovery, due diligence and development of new business opportunities, as well as overseeing the go-to-market strategy for Invoke’s portfolio companies. He is on the board of Darktrace and Featurespace.

Phil has an MA First-Class in Natural Sciences from Churchill College, University of Cambridge.

Ruth Angus

Ruth holds a PhD in Neuroscience from Bart’s and The London School of Medicine and Dentistry and a BScHons degree in Pharmacology from King’s College London. Her thesis investigated the role omega-3 fatty acids have in the astrocytic response after traumatic brain injury. At Invoke Capital, Ruth is responsible for evaluating potential investment opportunities and oversees the healthcare portfolio.

Ella Mamelok

Graduating in 2016, Ella holds a first-class BSc degree in Politics and International Relations from The University of Bristol. With experience in PR and Corporate Affairs, Ella is responsible for assisting in the Communications and Investor Relations function at Invoke Capital.